Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroimmunol ; 245(1-2): 93-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22370183

ABSTRACT

The aim of this study is to investigate the expression of P2X7R, IL-1beta and the ATP activity modulating ecto-apyrase CD39 on peripheral blood monocytes of MS patients and to observe the possible effects of Glatiramer Acetate (GA) on such expression. Twelve RR treatment-free MS patients were selected and peripheral blood monocytes were obtained. The expression of P2X7R, IL-1beta and CD39 on monocytes was investigated by qrt-PCR. The in vitro effects of GA on the expression of monocytes stimulated with BzATP (a potent P2X7R agonist)-were evaluated. Ten healthy donors (HDs) were similarly studied. Finally, 5 MS patients were given GA therapy and the monocytes obtained before treatment, after 3 and 12 months of GA treatment were similarly investigated. No differences were found in P2X7R, IL-1beta and CD39 expression between patients and controls. In MS Bz-ATP stimulated monocytes, GA pre-conditioning clearly downregulated P2X7R (p=0.003) but IL-1beta expression also showed a decreasing trend (p=0.07). Conversely, CD39 showed an increasing trend (p=0.07). Similar evidence was found in HDs. GA in vivo treatment induced a reduction in the expression that was clear for P2X7R and CD39 (p<0.05) but only not significant for IL-1beta after 12 months of treatment. Monocytes from both MS and control subjects express P2X7R, IL-1beta and CD39, and GA seems to interfere with such expression.


Subject(s)
Monocytes/drug effects , Monocytes/metabolism , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Peptides/pharmacology , Purinergic P2X Receptor Antagonists/pharmacology , Receptors, Purinergic P2X7/metabolism , Adult , Antigens, CD/biosynthesis , Antigens, CD/metabolism , Apyrase/biosynthesis , Apyrase/metabolism , Female , Glatiramer Acetate , Humans , Interleukin-1beta/biosynthesis , Interleukin-1beta/metabolism , Male , Middle Aged , Monocytes/immunology , Multiple Sclerosis, Relapsing-Remitting/metabolism , Primary Cell Culture , Receptors, Purinergic P2X7/biosynthesis
2.
J Neuroimmunol ; 233(1-2): 216-20, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21215463

ABSTRACT

Antibodies to MOG in serum have a dubious prognostic value in multiple sclerosis. The MOG recombinant protein conformational properties relevant to the antigenic activity are unknown. We employed a solid-phase ELISA based on a product (rMOG(ED)(His)(6)) expressed in E. coli after subcloning the cDNA of the extracellular domain of rat MOG, performing a refolding procedure on column and affinity purification. The far-UV Circular Dichroism (CD) spectra of rMOG(ED)(His)(6) showed a ß-sheet, a characteristic feature of the Ig-fold. However, in MS sera and controls we failed to detected IgM or IgG antibodies.


Subject(s)
Immunoglobulin G/blood , Immunoglobulin M/blood , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism , Myelin-Associated Glycoprotein/immunology , Protein Folding , Adult , Animals , Extracellular Space/chemistry , Extracellular Space/immunology , Female , Humans , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Male , Middle Aged , Multiple Sclerosis/diagnosis , Myelin Proteins , Myelin-Associated Glycoprotein/chemistry , Myelin-Oligodendrocyte Glycoprotein , Protein Structure, Tertiary/physiology , Rats , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...